IPO - SeaStar Medical Holding Corp

Form Type: S-1

Filing Date: 2025-05-19

Corporate Action: Ipo

Type: New

Accession Number: 000121390025045463

Filing Summary: SeaStar Medical Holding Corporation has filed a Form S-1 registration statement with the SEC, indicating a significant milestone for the company as it seeks to raise capital through an IPO. The registration statement covers the proposed resale of up to 4,736,406 shares of its common stock by Lincoln Park Capital, which purchased shares under a Purchase Agreement dated April 25, 2025. The offering is aimed at raising up to $15 million in gross proceeds. The document specifies that SeaStar is not selling any shares directly and will not receive proceeds from the stock sale, highlighting the financial structure of this offering. The company specializes in developing medical therapies aimed at treating critically ill patients, particularly focusing on its Selective Cytopheretic Device (SCD) that has received FDA approvals for pediatric patients. SeaStar is classified as a smaller reporting company and an emerging growth company, which allows it to meet reduced disclosure requirements. Recent developments include a notice from Nasdaq about potential delisting due to failing to meet the minimum market value requirement, which they have until June 22, 2025, to comply with. This filing allows SeaStar to advance its capital strategy while addressing its operational and compliance challenges.

Form Type: CORRESP

Filing Date: 2025-04-25

Corporate Action: Ipo

Type: New

Accession Number: 000121390025035637

Filing Summary: SeaStar Medical Holding Corporation has filed a request for the acceleration of the effective date of their Registration Statement on Form S-3 (File No. 333-286677). The company requests that the Registration Statement become effective as of 5:00 p.m., Eastern Time, on April 29, 2025, or as soon thereafter as practicable. The filing is communicated to the United States Securities and Exchange Commission and seeks confirmation of the effective date orally through their counsel, Dorsey & Whitney LLP. The letter is signed by Eric Schlorff, Chief Executive Officer of SeaStar Medical Holding Corporation.

Form Type: 424B5

Filing Date: 2025-02-03

Corporate Action: Ipo

Type: New

Accession Number: 000121390025009443

Filing Summary: SeaStar Medical Holding Corporation is offering 713,000 shares of its common stock and Pre-Funded Warrants to purchase 2,816,412 shares of common stock to a single institutional investor. The offering price per share is $1.70, and the exercise price for each Pre-Funded Warrant is $1.699. The offering is intended to enhance capital for the company, which has developed a proprietary therapy platform to address hyperinflammation through its Selective Cytopheretic Device (SCD). The company has obtained regulatory approval for its pediatric SCD product 'QUELIMMUNE.' Additionally, the document states that there is an ongoing pivotal clinical trial for adult patients with acute kidney injury. The proceeds from this offering are estimated to be approximately $6 million before expenses, and the total expenses are expected to be around $500,000. The document discloses recent developments including a public reprimand from Nasdaq regarding a prior transaction which was determined to exceed 20% of the company's outstanding shares without sufficient shareholder approval. Furthermore, the summary notes the implications of being a smaller reporting company and the associated reduced disclosure requirements, alongside the plans for proceeds usage, which primarily focuses on development and commercialization activities.